While our study provides evidence using LUAD cells harboring KRAS or EGFR mutations and KRASG12D-driven lung adenocarcinoma, it would be valuable to investigate whether this mechanism occurs in other cancers with different oncogenic changes that consistently activate ERK. This evidence concerns the gene KRAS and cancer.